Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients

Xiao, Zefen; Yang, Zhilin; Liang, Jun; Miao, Yan; Wang, Mei; Yin, Wei; Gu, Xianfeng; Zhang, De Chao; Zhang, Ru Gang; Wang, Liang Jun

doi:10.1016/s0003-4975(02)04401-6

Cited by 219 publications

(226 citation statements)

References 3 publications

Supporting

Mentioning

208

Contrasting

Unclassified

Order By: Relevance

“…For patients with neck or upper thoracic esophageal carcinoma, radiotherapy is a major treatment method now. Esophageal carcinoma is often accompanied with supraclavicular or superior mediastinal lymph node metastasis, and correlated with poor prognosis (Kawahara et al, 1998;Kurokawa et al, 2003;Xiao et al 2003;Xiao et al, 2005;Tachimori et al, 2011) Research showed that IMRT technique can not only elevate target dose, but possesse advantages of higher target conformity, higher dose uniformity and better protection of sensitive organs compared with conventional conformal radiotherapy (Nutting et al, 2001;Fu et al, 2004;Wu et al, 2004;Chandra et al, 2005;Wang et al, 2006;Fenkell et al, 2008). It was reported 5~7 intensity-modulated beams were more effective in target dose uniformity, target conformity and radiation dose to organs at risk when comparing the effect of IMRT with that of 3D-CRT on 5 cases of upper esophageal carcinoma using simultaneous integrate boost (Fu et al, 2004).…”

Section: Discussionmentioning

confidence: 99%

“…Neck or upper thoracic esophageal carcinoma with lymph node metastasis is a common clinical disease with poor prognosis (Kawahara et al, 1998;Kurokawa et al, 2003;Xiao et al 2003;Xiao et al, 2005;Tachimori et al, 2011). Due to hypoxia, metastatic lymph node is difficult to control by radiotherapy with the conventional dose, especially those large metastatic lymph nodes (Watarai et al, 1992).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy Analysis of Simplified Intensity-modulated Radiotherapy with High or Conventional Dose and Concurrent Chemotherapy for Patients with Neck and Upper Thoracic Esophageal Carcinoma

Zhu

Zhou²,

Chen³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

For patients with neck and upper thoracic esophageal carcinoma, it is difficult to control lymph node metastases with conventional dose therapy. In this study, we assessed the feasibility of simplified intensity-modulated radiotherapy (sIMRT) and concurrent chemotherapy for 44 patients and boosted high-dose to metastatic lymph nodes.Three radiation treatment volumes were defined: PGTVnd, with which 68.1Gy was delivered in high dose group (hsIMRT group), and 60Gy in the conventional dose group (csIMRT group); PTV1, featuring 63.9Gy in the hsIMRT group and 60Gy in the csIMRT group; PTV2, with 54Gy given to both groups. The sIMRT plan included 5 equi-angular coplanar beams. All patients received the cisplatin and 5-FU regimen concurrently with radiotherapy. The treatment was completed within six weeks and one case with grade three acute bronchitis was observed in hsIMRT group. For esophageal lesions, 80% complete response (CR) and 20% partial response (PR) rates were found in the hsIMRT group, and 79.2% CR, with 20.8% PR, in the csIMRT group; for lymph node lesions, 75% CR and 25% PR rates were observed in the hsIMRT group, with 45.8% and 37.5% respectively in the csIMRT group (P <0.05). The differences in 1-, 2-and 3-year relapse-free survival rates were all statistically significant (P <0.05). The major toxicity observed in both groups was Grade I~II leucopenia. sIMRT can generate a desirable dose distribution in treatment of neck and upper thoracic esophageal carcinoma with a better shortterm efficacy. Boosted high dosing to metastatic lymph nodes can increase the relapse-free survival rate.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Efficacy Analysis of Simplified Intensity-modulated Radiotherapy with High or Conventional Dose and Concurrent Chemotherapy for Patients with Neck and Upper Thoracic Esophageal Carcinoma

Zhu

Zhou²,

Chen³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…18 In spite of comprehensive available treatment, including chemotherapy, surgery and radiotherapy, the overall 5-year survival rate for patients with esophageal squamous cell carcinoma (ESCC), the most common form of esophageal cancer, remains low, at 10-40%, because of advanced disease, metastasis and resistance of the tumor to chemotherapy and radiotherapy. [19][20][21] Cisplatin is the most frequently used chemotherapeutic agent for ESCC. However, given that resistance to cisplatin limits the success of treatment, elucidation of the mechanisms that regulate cisplatin resistance in ESCC is urgently needed.…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma

et al. 2011

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are endogenous non-coding RNAs that function as negative regulators of gene expression. Alterations in miRNA expression have been shown to affect tumor growth and response to chemotherapy. In this study, we explored the possible role of miRNAs in cisplatin resistance in esophageal squamous cell carcinoma (ESCC). First we assessed the sensitivity of nine human ESCC cell lines (KYSE series) to cisplatin using an in vitro cell viability assay, and then we compared the miRNA profiles of the cisplatin-sensitive and -resistant cell lines by miRNA microarray analysis. The two groups showed markedly different miRNA expression profiles, and 10 miRNAs were found to be regulated differentially between the two groups. When miR-141, which was the most highly expressed miRNA in the cisplatin-resistant cell lines, was expressed ectopically in the cisplatin-sensitive cell lines, cell viability after cisplatin treatment was increased significantly. Furthermore, we found that miR-141 directly targeted the 3¢-untranslated region of YAP1, which is known to have a crucial role in apoptosis induced by DNA-damaging agents, and thus downregulated YAP1 expression. Our study highlights an important regulatory role for miR-141 in the development of cisplatin resistance in ESCC.

show abstract

“…Although advances in diagnostic methods and health education have contributed to discovery of the disease in its early stages, many cases are still not detected until the advanced stage. Despite the use of modern surgical techniques in conjunction with multitreatment modalities such as radio-and chemotherapy, the overall 5-year survival rate remains 40 -60% (1)(2)(3)(4). In an effort to better understand this disease and predict its clinical outcome, numerous molecular markers for tumor progression and prognosis, e.g., STMY3 (5), interleukin 6 (6), C1orf10 (7), and EC45 (8), and for lymph node metastasis, e.g., caveolin-1 (9), EphA2 (10), FAK (11), cystain B (12), and MMP-12 (13), have been identified.…”

Section: Introductionmentioning

confidence: 99%

Gene-Expression Profile Changes Correlated with Tumor Progression and Lymph Node Metastasis in Esophageal Cancer

Tamoto¹,

Tada

Murakawa³

et al. 2004

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: The purpose of this research was to identify molecular clues to tumor progression and lymph node metastasis in esophageal cancer and to test their value as predictive markers.Experimental Design: We explored the gene expression profiles in cDNA array data of a 36-tissue training set of esophageal squamous cell carcinoma (ESCC) by using generalized linear model-based regression analysis and a feature subset selection algorithm. By applying the identified optimal feature sets (predictive gene sets), we trained and developed ensemble classifiers consisting of multiple probabilistic neural networks combined with AdaBoosting to predict tumor stages and lymph node metastasis. We validated the classifier abilities with 18 independent cases of ESCC. Conclusion: We suggest that these characteristic genes will provide useful information for understanding the malignant nature of ESCC as well as information useful for personalizing the treatments.

show abstract

Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients

Cited by 219 publications

References 3 publications

Efficacy Analysis of Simplified Intensity-modulated Radiotherapy with High or Conventional Dose and Concurrent Chemotherapy for Patients with Neck and Upper Thoracic Esophageal Carcinoma

Efficacy Analysis of Simplified Intensity-modulated Radiotherapy with High or Conventional Dose and Concurrent Chemotherapy for Patients with Neck and Upper Thoracic Esophageal Carcinoma

MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma

Gene-Expression Profile Changes Correlated with Tumor Progression and Lymph Node Metastasis in Esophageal Cancer

Contact Info

Product

Resources

About